Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
Statement: Zantac (ranitidine) litigation
In response to the Sargon ruling by the California state court in respect of the Goetz case, GSK plc issued the following statement.
China National Medical Products Administration accepts regulatory submission for Nucala (mepolizumab) in severe eosinophilic asthma
The China National Medical Products Administration (NMPA) has accepted for review a new drug application for Nucala (mepolizumab)
GSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate
MenABCWY combination vaccine candidate met all its primary endpoints of the pivotal phase III clinical trial
US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate
Committee votes unanimously that the data support the effectiveness of the vaccine and 10-2 that the data support the safety of the vaccine
ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1
ViiV Healthcare announced positive 12-month findings from the SOLAR study.
Landmark New England Journal of Medicine publication reinforces potential of GSK’s respiratory syncytial virus older adult vaccine candidate
First peer-reviewed publication of phase III RSV vaccine data in older adults, including those with comorbidities who are most at risk.
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023
Other key data to be presented include new HIV prevention findings for long-acting cabotegravir and predictors of response to N6LS
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer
Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial
US FDA Advisory Committee votes in support of trials designed to evaluate Jemperli (dostarlimab-gxly) as a potential treatment for mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer
In January 2023, the US FDA granted dostarlimab-gxly Fast Track designation for the treatment of dMMR/MSI-H locally advanced rectal cancer.
GSK announces results from 17-year retrospective study on US clinical trial diversity
Study examined clinical trial diversity across 495 GSK trials involving over 100,000 participants.
Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis
Jesduvroq is the only oral HIF-PHI approved in the US, offering adults on dialysis with anaemia of CKD a new oral treatment option
GSK delivers strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations
Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines
Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis
GSK plans to initiate a phase II/III trial for systemic sclerosis associated interstitial lung disease (SSc-ILD) in the first half of 2023.
VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
SARS-CoV-2 spike protein vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the EU
GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
A strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing programme
GSK announces new global headquarters in central London
GSK today announced that its new global headquarters will be in central London. The company will move to the new headquarters in 2024.
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
GSK today announced new 48-week data from the MOMENTUM phase III trial...
PERLA phase II trial of Jemperli (dostarlimab) plus chemotherapy shows positive results in first-line metastatic non-squamous non-small cell lung cancer
PERLA is the largest global head-to-head trial of PD-1 inhibitors in this patient population
Statement: Zantac (ranitidine) litigation
MDL Court has dismissed all cases alleging the five remaining cancers in the MDL
Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer
Regulatory submissions based on the trial results are planned for the first half of 2023.